<DOC>
	<DOC>NCT00957788</DOC>
	<brief_summary>This research study involves an experimental drug (NST_001) and a delivery system. The main purpose of this research study is to investigate the safety of NST-001, delivered directly to the inner ear for the treatment of tinnitus.</brief_summary>
	<brief_title>Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus</brief_title>
	<detailed_description />
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Patients able to provide voluntary consent. Severe tinnitus in one ear that began no more than ten years ago. Ear to be treated must be deaf or have profound hearing loss. Subjects with cardiac disease or hypertension, must have stable disease for at least 6 months. Subject must have intact cochlear nerve on the ear to be treated. Women of childbearing potential (i.e., not postmenopausal or surgically sterilized) must agree to use adequate birth control methods as recommended by the study physician. Current diagnosis of bilateral tinnitus. Current diagnosis or history of pancreatitis. Females that are pregnant or lactating. Use of investigational drugs within the previous 30 days. History of drug dependency or other substance abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>tinnitus</keyword>
	<keyword>acouphenes</keyword>
	<keyword>ear</keyword>
	<keyword>ringing</keyword>
	<keyword>buzzing</keyword>
	<keyword>roaring</keyword>
	<keyword>hissing</keyword>
	<keyword>clicking</keyword>
</DOC>